Relapsed multiple myeloma or refractory multiple myeloma research hub

Pomalidomide Specific Targeting in Relapsed and Refractory Myeloma (MUK Seven)

This UK clinical trial is for people with multiple myeloma that has returned or stopped responding to treatment. It looks at whether adding a medicine called cyclophosphamide to the usual two-drug treatment (pomalidomide and dexamethasone) works better to control the cancer and improve care.